Revivicor, Inc.
Revivicor is dedicated to providing organs from gene-edited pigs to address the critical shortage of human organs for transplant through xenotransplantation. Their mission is to alleviate human suffering, heal patients in need, and restore quality of life by developing scalable, genetically-engineered pig organs for transplantation. They focus on innovative gene editing technologies and have a history of pioneering in the field of xenotransplantation, including the development of gene-edited pigs and successful preclinical and clinical studies.
Industries
Nr. of Employees
small (1-50)
Revivicor, Inc.
Blacksburg, Virginia, United States, North America
Patents
Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
US-11179496-B2
View Details
Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
US-11179496-B2
View DetailsProducts
Gene-edited porcine hearts (development-stage)
Genetically modified pig hearts engineered to reduce rejection and other adverse immunologic responses; used as development-stage grafts in clinical and preclinical settings.
Gene-edited porcine kidneys (development-stage)
Genetically modified pig kidneys engineered to reduce rejection, inflammation, and coagulation; intended for investigational transplant use in end-stage renal disease.
Thymus-containing gene-edited porcine kidney (development-stage)
A development-stage porcine kidney product that includes thymic tissue intended to modulate immune interactions after transplantation.
Alpha-gal–null pigs and derived products (FDA-authorized line for specified uses)
Pigs with inactivated GGTA1 producing tissues and materials with undetectable alpha-gal for potential use in food products, excipients, devices, drugs, or biologics; the genomic alteration received regulatory authorization for specified uses.
Gene-edited porcine hearts (development-stage)
Genetically modified pig hearts engineered to reduce rejection and other adverse immunologic responses; used as development-stage grafts in clinical and preclinical settings.
Gene-edited porcine kidneys (development-stage)
Genetically modified pig kidneys engineered to reduce rejection, inflammation, and coagulation; intended for investigational transplant use in end-stage renal disease.
Thymus-containing gene-edited porcine kidney (development-stage)
A development-stage porcine kidney product that includes thymic tissue intended to modulate immune interactions after transplantation.
Alpha-gal–null pigs and derived products (FDA-authorized line for specified uses)
Pigs with inactivated GGTA1 producing tissues and materials with undetectable alpha-gal for potential use in food products, excipients, devices, drugs, or biologics; the genomic alteration received regulatory authorization for specified uses.
Services
Support for clinical teams and academic partners in planning, supplying, and documenting development-stage xenotransplantation procedures and studies.
Provision of donor pigs raised in pathogen-controlled facilities for use in preclinical research or development-stage clinical procedures.
Support for clinical teams and academic partners in planning, supplying, and documenting development-stage xenotransplantation procedures and studies.
Provision of donor pigs raised in pathogen-controlled facilities for use in preclinical research or development-stage clinical procedures.
Expertise Areas
- Xenotransplantation product development
- Large-animal genetic engineering
- Cloning and animal production (SCNT)
- Preclinical translational research
Key Technologies
- Precision multiplex gene editing (knockouts and transgene insertion)
- Somatic cell nuclear transfer (SCNT)
- Designated pathogen-free breeding and biosecure animal facilities
- Genomic screening and functional validation assays
News & Updates
Announcement of recent milestones in xenotransplantation programs.
A second successful pig heart transplant into a human patient.
A study demonstrating progress in pig kidney xenotransplantation.
A groundbreaking study published in Nature Medicine about pig heart transplantation.
A study demonstrating consistent survival in pig kidney xenotransplantation.
A review article discussing the physiological basis for xenotransplantation.
Announcement of recent milestones in xenotransplantation programs.
A second successful pig heart transplant into a human patient.
A study demonstrating progress in pig kidney xenotransplantation.
A groundbreaking study published in Nature Medicine about pig heart transplantation.
A study demonstrating consistent survival in pig kidney xenotransplantation.
A review article discussing the physiological basis for xenotransplantation.